Browse Articles

Discover research articles across all indexed journals

Evaluation of methylene blue restaining versus conventional hydrogen peroxide decolorization in immunohistochemical diagnosis of melanoma

Scientific Reports Weisong Wan, Le Wang, Yuye Zeng et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89186-8

Abstract This study seeks to address the challenge of melanoma identification in immunohistochemical (IHC) diagnosis, which is complicated by the similar coloration of melanin and DAB (Diaminobenzidine) staining, by introducing methylene blue counterstaining as an innovative solution. We compared the effectiveness of methylene blue counterstaining with that of the traditional hydrogen peroxide bleaching method in the diagnosis of melanoma. The study included 46 paraffin-embedded melanoma samples, and the staining efficacy for markers such as Melan A, HMB-45, PRAME, and Ki-67 was assessed via both methods. The results demonstrated that methylene blue counterstaining effectively converted the brownish-yellow melanin granules to a deep green color, significantly enhancing contrast and clarity with DAB staining. The average contrast and clarity scores for the methylene blue counterstaining method were 1.96 ± 0.21 and 1.91 ± 0.28, respectively, which were significantly greater than those of the conventional IHC group and the hydrogen peroxide bleaching group (P < 0.01). Furthermore, methylene blue counterstaining did not cause noticeable tissue damage or cellular morphology distortion, with tissue integrity scores comparable to those of the conventional IHC group (P > 0.05). Although the contrast and clarity also improved in the hydrogen peroxide bleaching group, it resulted in a significant decrease in tissue integrity (P < 0.01). This study is the first to apply methylene blue counterstaining in melanoma IHC analysis, demonstrating its advantages in enhancing staining quality, simplifying procedural workflows, and preserving antigenicity. This method provides a novel and effective tool for the pathological diagnosis of melanoma, potentially improving diagnostic accuracy and reliability.

Evaluation of post radiotherapy PSA as a prognostic and predictive biomarker in high risk prostate cancer: A secondary analysis of RTOG 0521.

Journal of Clinical Oncology Paul Koffer, Christina Raker, Thomas A. DiPetrillo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.384

384 Background: RTOG 0521 was a randomized trial of radiotherapy (RT) and 24 months of androgen deprivation (ADT) with and without docetaxel (D) in high risk prostate cancer. We sought to evaluate whether post RT PSA was prognostic of outcomes and predictive of the benefit of D. We hypothesized that patients with a higher post RT PSA derive a benefit from D while those with a lower post RT PSA would derive no benefit. Methods: Patients treated on RTOG 0521 received 72-75.6 Gy in 40-42 fractions 8 weeks after starting ADT. In the experimental arm, D was started 28 days after RT. Per protocol, a PSA was to be drawn within 28 days after completion of RT (PRT-PSA). Hazard ratios (HRs) for PRT-PSA (>/≤ median level) were estimated by Cox proportional hazards regression for overall survival (OS) and Fine-Gray competing risks regression for prostate specific mortality (PCSM) and distant metastasis (DM), adjusting for baseline characteristics. As a sensitivity analysis for non-proportional hazards, HRs were estimated with follow up censored at 10 years. Results: PRT-PSA was available in 276/563 patients (114/281 in ADT alone and 162/282 in the ADT+D arm). PRT-PSA was drawn at a median of 15 days from the completion of RT and 120 days from randomization. 25% of patients had a PRT-PSA >0.1 ng/L. Patients with PSA >0.1 ng/mL had worse OS (HR 2.39, 95% confidence interval [CI] 1.51-3.79), PCSM (HR 3.78, 95% CI 1.87-7.62), and DM (HR 3.54, 95% CI 1.99-6.31) (all p<0.001). Baseline characteristics including Gleason score, T-stage, pretreatment PSA, performance status, and age were similar between patients with a PRT-PSA >0.1 and ≤ 0.1 ng/mL. In patients with PRT-PSA >0.1 ng/mL, there was no benefit seen with the addition of D to ADT alone in terms of OS (HR 1.06, p=0.88), PCSM (HR 0.97, p=0.96), or DM (HR 1.16, p=0.75). In patients with PRT-PSA ≤0.1 ng/mL, there was a benefit from the addition of D to ADT alone in terms of OS (HR 0.55, p=0.03) and PCSM (HR 0.36, p=0.02) but no significant benefit in terms of DM (HR 0.74, p=0.40). Results were similar in the sensitivity analysis for patients with PRT-PSA >0.1 ng/mL (OS HR 1.36, p=0.42; PCSM HR 1.71, p=0.39) and patients with PRT-PSA ≤0.1 ng/mL (OS HR 0.41, p=0.003; PCSM HR 0.26, p=0.006). Conclusions: PRT-PSA was prognostic of OS, DMFS, and DM in patients with high risk prostate cancer treated with RT and long term ADT +/- D. Despite having a worse prognosis, patients with PRT-PSA >0.1 ng/mL did not benefit from the addition of D while those with PRT-PSA ≤ 0.1 ng/mL had an OS and PCSM benefit from D. Clinical trial information: NCT00288080 . PRT-PSA (ng/mL) ADT, event/total ADT+D, event/total Adjusted HR (95% CI) Adjusted HR (95% CI)-10 y OS  ≤0.1 28/79 31/127 0.55 (0.32-0.95) 0.41 (0.23-0.73)  >0.1 21/35 18/35 1.06 (0.51-2.19) 1.36 (0.64-2.88) PCSM  ≤0.1 13/79 7/127 0.36 (0.15-0.87) 0.26 (0.10-0.67)  >0.1 15/35 11/35 0.97 (0.29-3.21) 1.71 (0.51-5.70) DM  ≤0.1 14/79 16/127 0.74 (0.37-1.50) 0.75 (0.37-1.50)  >0.1 16/35 16/35 1.16 (0.47-2.85) 1.09 (0.43-2.75)

Primary sarcomas of urinary bladder: A SEER analysis.

Journal of Clinical Oncology Joseph Han, Hyun Lee, Ayush Kaushish et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.878

878 Background: Primary bladder sarcoma (PBS) is a rare entity. In this study, we analyzed demographics, clinical characteristics, and survival outcomes of PBS using the Surveillance, Epidemiology and End Results (SEER) database. Methods: We identified patients with urinary bladder sarcoma in the SEER database from the years 2000 to 2020 using the primary cancer site codes for urinary bladder as well as histological codes (ICD-O-3) that match the list of sarcoma histology found in the NCCN soft tissue sarcoma and bone cancer guidelines. Data for demographics, disease extent, median overall survival (OS), and treatment modalities were obtained. Sarcomas mixed with carcinomas, so-called carcinosarcomas, were included in the analysis. From the same database, OS data on urothelial carcinomas were obtained for comparison. Results: During the period of analysis, a total of 349,326 patients with primary bladder neoplasms were identified. Among them, 707 (0.002%) patients had PBS. The majority were Caucasian (71.9%) followed by Hispanics (12.9%) and African Americans (11.0%). There were 445 males (62.9%) with PBS. The most common histology was carcinosarcoma (40.9%), followed by leiomyosarcoma (20.4%), rhabdomyosarcoma (13%), and unspecified sarcoma (9.3%). Among the 654 patients with known extent of disease, 56.7%, 24.9%, and 18.3% had localized, locoregional, and distant metastatic disease, respectively. OS for patients with localized, regional, and distant diseases were 32, 12, and 4 months, respectively (P<0.0001). Bladder sarcomas were associated with worse survival than urothelial carcinomas (14 months vs. 92 months, P<0.01). OS was longer in patients with pure sarcomas compared to patients with mixed sarcomas (26 months vs. 9 months, P< 0.001). Among the 697 patients with treatment data available, 34 (4.9%) received chemotherapy only, 468 (67.1%) received surgical resection only, 152 (21.8%) received both, and 43 (6.2%) received neither. Both chemotherapy and surgery were associated with longer median OS. Those who received chemotherapy showed a median OS of 42 months compared to 9 months seen in the no chemotherapy group (P<0.001). As for surgical resection, median OS of those who underwent surgery was 16 months compared to 8 months in those who did not (P=0.014). Conclusions: Bladder sarcomas are rare and associated with worse outcomes when compared to urothelial carcinoma. Carcinosarcomas are associated with worse survival when compared with pure sarcomas. More than half of the bladder sarcomas were diagnosed as localized disease and survival was better when compared with locoregional or distant disease. Chemotherapy and surgical resection were associated with longer median OS, but prospective studies are needed to ascertain these findings after controlling for confounders.

Mortality risk in clinical T1a renal cell carcinoma (RCC) with synchronous metastasis (SM): A comparative analysis of National Cancer Database (NCDB).

Journal of Clinical Oncology Melis Gür, Luke Wang, Franklin Liu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.513

513 Background: The incidence of RCC has been rising, largely due to increased incidental detection from widespread imaging. Although SM with a primary renal tumor measuring <4 cm (cT1a) is uncommon, its presence may influence survival outcomes and utility of cytoreductive nephrectomy. We sought to examine trends, metastatic patterns, treatments and survival outcomes of cT1a RCC with SM. Methods: All cases of RCC (age ≥ 18 years), diagnosed between 2004-2019, were extracted from the NCDB. The Cochran-Armitage test was utilized for trend analyses. Multivariable analyses were conducted to compare variables associated with all-cause mortality across metastatic sites. Results: Overall, 263,911 patients with T1a RCC were included in the analysis. Of these, 114,661 patients (43.4%) had cT1a tumor stage and within this group, 2,275 (2.0%) presented with SM. From 2004-2019, the proportion of SM cT1a decreased from 3.39% to 2.08% (AAPC=-0.037%; Cochran-Armitage p=0.830). The median follow-up was 8.8 months. The most common site of metastasis was bone (59%), followed by lung (35%), liver (16%), and brain (12%). Among SM cT1a patients, 11% underwent radical nephrectomy, 4.7% partial nephrectomy, 15.4% metastasectomy, and 45.2% received systemic therapy. Variables associated with all-cause mortality demonstrated in the table. Conclusions: Uniquely, bone was the most common metastatic site in cT1a RCC with synchronous metastasis, contrasting with the typical lung predominance in larger tumors. Primary tumor resection and receipt of systemic therapy showed potential survival benefits in patients with isolated metastases, while metastasectomy improved survival in brain-only metastases but not in bone-, lung-, or liver-only metastases.These findings highlight the heterogeneous nature of tumor biology in small renal masses and underscore the importance of tailored, multimodal treatment strategies for effective management of cT1a RCC with SM. Multivariable Cox regression models demonstrating variables associated with all-cause mortality in cT1a RCC with SM to lung, bone, liver, and brain. SM to Lung SM to Bone SM to Liver SM to Brain Variables HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value Age 0.98 (0.96-1.01) 0.178 1.03 (1.02-1.04) <0.001 1(0.97- 1.03) 0.989 0.99(0.96- 1.03) 0.748 Surgery of Primary Site Nephrectomy 0.08(0.01- 0.72) 0.047 0.35(0.14- 0.86) 0.056 0.22(0.06-0.78) 0.039 0.08(0.02- 0.41) 0.005 Partial Nephrectomy 0.02(0.00- 0.31) 0.013 0.23(0.09- 0.60) 0.011 0.13(0.01- 2.35) 0.165 0.1(0.01- 0.97) 0.047 Metastasectomy 0.91(0.50- 1.67) 0.759 0.81(0.59- 1.10) 0.169 3.14(0.90- 11.0) 0.074 0.26(0.10- 0.68) 0.006 Systemic Therapy 0.36(0.23-0.57) <0.001 0.57(0.44- 0.74) <0.001 0.41(0.20- 0.85) 0.033 0.22(0.10- 0.48) <0.001 HR = hazard ratio, CI = confidence interval.

Treatment patterns and clinical outcomes in patients with metastatic urothelial carcinoma in England: A retrospective observational study.

Journal of Clinical Oncology Tinevimbo Shiri, Max Nievaart, Simran Gill et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.740

740 Background: In England, platinum-based chemotherapy with or without an immune checkpoint inhibitor is the standard-of-care for mUC patients. However, treatment patterns following first-line therapy remain unclear. There is a need to collect real-world data to enable an improved understanding of the clinical management of mUC in the National Health Service (NHS) and associated outcomes. Methods: This retrospective study obtained routine data for all patients diagnosed with mUC in England between January 2016 and December 2021 from the National Cancer Registration and Analysis Service (NCRAS). A treatment-based algorithm was developed to approximate progression to metastatic disease for those patients who had non-metastatic UC (Stage I-III). Variables collected include patient demographics, tumour characteristics, diagnostic tests, comorbidities, healthcare resource use, systemic anti-cancer therapy (SACT) and distributions of patients by lines of treatment. Kaplan-Meier methods were used to calculate overall survival (OS). Results: Of 61,816 patients diagnosed with UC between 2016 and 2021, 10,787 patients had mUC (stage IV (79.7%) at diagnosis or stage I-III (20.3%). The median age at diagnosis was 73.9 years, with 66.0% being male. Patients treated with anti-PD-L1 had a median age of 68.8 years. Only 36.5% (n = 3,942) received first-line therapy, with 24.3% (n = 959) reaching second-line therapy, while third-line therapy was delivered to 4.0% (n = 158) and fourth-line therapy to just 0.5% (n = 19) of patients with derived lines of therapy. The most common first-line regimen was ‘carboplatin + gemcitabine’ (n = 1,497; 38.0%), followed by ‘cisplatin + gemcitabine’ (n = 1,153; 29.2%). Pembrolizumab was the most common regimen administered at second line (n = 284; 29.6%) and remained the most common regimen at third line (n = 52; 32.9%). For the entire cohort, including patients that did not receive an active treatment, 12-month survival probability was 29.0%. The survival probabilities for patients treated at first-line, and reaching second-line and third-line, were 45.0%, 34.0%, and 30.0%, respectively. For the entire cohort, including patients that did not receive an active treatment, 12-month survival probability was 29.0%. The survival probabilities for patients treated at first-line, and reaching second-line and third-line, were 45.0%, 34.0%, and 30.0%, respectively. Conclusions: A high attrition rate in SACT was observed in mUC patients, and a poor prognosis indicated by a median OS of only 5.4 months from diagnosis. New treatment options particularly in the second-line setting could improve outcomes for patients. Further real-world studies are needed to evaluate their impact within routine clinical practice.

Differences in sensory nerve block between levobupivacaine and bupivacaine at low concentrations in humans and animals

PLoS ONE Akiyuki Sakamoto, Satoshi Tanaka, Takashi Ishida et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0306591

Physiochemical properties of levobupivacaine and bupivacaine are identical, but pharmacokinetic and pharmacodynamics properties differ due to stereoselective interactions at the molecular sites of action. An evaluation of nerve block characteristics is essential for optimal clinical application. This study compared the sensory blocking characteristics of levobupivacaine to bupivacaine in humans and model animals. Levobupivacaine and bupivacaine were compared for sensory block efficacy using a randomized, double-blinded, crossover study design. Eighteen healthy volunteers were randomized to receive levobupivacaine or bupivacaine by subcutaneous injection into the forearm, followed by the other drug 1 week later with injection order counterbalanced across subjects. Tactile detection and mechanical pain thresholds were determined using von Frey hairs and thermal pain threshold using a thermal stimulator. Effects of levobupivacaine and bupivacaine, on the spiking activity of spinal dorsal horn (SDH) neurons evoked by innocuous or noxious stimuli were also compared in anesthetized Sprague–Dawley rats by in vivo extracellular recordings. There were no significant differences in mechanical and thermal pain thresholds following levobupivacaine or bupivacaine injection at 0.025%, 0.0625%, and 0.125%. There was also no significant difference in tactile detection threshold following levobupivacaine or bupivacaine injection at 0.125%. However, tactile detection threshold was significantly higher after administration of bupivacaine at 0.025% and 0.0625% compared to equivalent doses of levobupivacaine. Subcutaneous injection of bupivacaine at 0.05% also induced significantly greater inhibition of SDH neuron spiking activity evoked by innocuous stimuli compared to an equivalent dose of levobupivacaine, while there was no significant difference in suppression of spiking activity evoked by noxious stimuli. Low-dose bupivacaine induces greater suppression tactile sensation than low-dose levobupivacaine. Thus, low-dose levobupivacaine demonstrates relatively greater blocking selectivity for noxious over innocuous stimuli compared to low-dose bupivacaine. Levobupivacaine may be advantageous for applications where pain must be suppressed but non-nociceptive sensations maintained.

Disaster victim identification: the co-utilisation of applied biosystems RapidHIT ID system and DJI Matrice 300 drone for onsite DNA analysis

Scientific Reports Natassya Ezzaty Mohd Sabri, Siti Hamimah Sheikh Abdul Kadir, Mansharan Kaur Chainchel Singh et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88750-6

Automated classification of treatment state of patients with prostate cancer from structured medical record data to help enhance care.

Journal of Clinical Oncology Richard Nishan Boyajian, Ashleigh Kowtoniuk, Sharon Hensley Alford et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.427

427 Background: The number of US prostate cancer (PCa) cases is projected to expand exponentially while the oncology workforce stagnates. The increase in clinic demand requires innovative technologic approaches for patient management. We are developing a process for automatically tracking patients across the care continuum which can flag patients overdue for follow-up, send alerts when patients recur, and thereby optimize clinic resources. In order to place patients into the correct care pathway, their disease status must be correctly classified, which is the focus of the current study. Methods: Clinician specialist input was used to define five mutually exclusive care states in PCa (newly diagnosed, active surveillance, active treatment, post-treatment surveillance, and metastatic). Using a variable set defined to classify each care state, decision tree modeling was applied to abstracted, de-identified data from 150 patients seen in the Dana-Farber/Brigham Cancer Center radiation oncology clinic between 5/14 and 8/14/2024 to validate model care state classification. Model output and a case summarization were presented in an interactive web-interface designed using user experience principles. Through a secure login, a provider accessed the data for each case and recorded if the care state assignment and case summary were accurate. Results: The concordance between the model classification and provider assignment was 100%. The model correctly sorted the care states of each of the patients, of which the distribution was 0% newly diagnosed, 1% active surveillance, 12% active treatment, 73% post-treatment surveillance, and 13% metastatic The interactive web interface included graphical and table views of PSA test values with automatic calculation of doubling time and velocity. In addition, treatment events (prostatectomy, radiation, hormone therapy) were overlaid on the PSA graph for easy clinical analysis. A treatment summary table provided a chronologic view for each patient. Conclusions: The care state assignment model was able to correctly classify the care state of all 150 patients in this cohort for which structured, provider abstracted data was available. The next steps in clinical implementation will be EMR integration, automatic record abstraction, and end-user testing. We have already begun work to automatically ingest and parse PCa records using natural language processing and expand the user interface to include a patient care journey map, generation of a pre-visit clinical note, and care optimization protocols. The goal is to provide a tool that will decrease time for case review and appointment preparation, give case prioritization alerts based on PSA testing results, and automatically monitor surveillance care compliance thus optimizing clinic resources while ensuring no patient is lost to follow-up.

A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial.

Journal of Clinical Oncology William Aronson, Tristan Grogan, Pei Liang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.312

312 Background: Men on active surveillance for prostate cancer are extremely interested in dietary changes or supplements to prevent progression of their disease. There are presently no prospective trials supporting such changes. We sought to determine if a high omega-3, low omega-6 fatty acid diet with fish oil capsules (D+FO) decreases proliferation (Ki-67) in prostate biopsies in men with prostate cancer on active surveillance over a 1-year time period. Methods: In this Phase II, prospective randomized trial, men (N=100) with grade group 1 or 2 prostate cancer that elected active surveillance were randomized to the D+FO or a control group. Same site prostate biopsies were obtained at baseline and 1-year tracked using an image-fusion device. The primary endpoint was the change in Ki-67 index from baseline to 1-year from same site biopsies compared between the groups. Ki-67 index was determined using multiplex immunofluorescence analysis. Secondary outcomes included compliance, grade group, maximum tumor length, the Decipher 22 gene score, serum PSA, lipid levels, and adverse events. Results: The Ki-67 index decreased in the D+FO group by approximately 15% from baseline to 1-year (1.34% at baseline, 1.14% at 1-year) and increased in the control group by approximately 24% from baseline to 1-year (1.23% at baseline, 1.52% at 1-year) resulting in a statistically significant difference in the change of Ki-67 index between the groups (95% CI 2%, 52%, p=0.043). There was no significant difference in the secondary outcomes grade group, tumor length, decipher genomic score or PSA between the two groups. There was a significant decrease in serum triglyceride (p=0.016) and serum colony stimulating factor-1 (p=0.017) in the D+FO group compared to control. Four patients in the D+FO group were withdrawn from the trial due to adverse events related to the FO. Conclusions: A high omega-3, low omega-6 diet with FO for 1-year resulted in a significant reduction in Ki-67 index (compared to the control group), a biomarker for prostate cancer progression, metastasis and death. These findings support future Phase III trials incorporating this intervention in men on active surveillance. Clinical trial information: NCT02176902 .

Ethnic disparities in clinical trials for FDA-approved drugs in urothelial cancer: An analysis in the post-COVID-19 era (2020-2024).

Journal of Clinical Oncology Bruno R. Bastos, Michael A. Schwartz, Oleg Gligich et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.677

677 Background: Ethnic and racial disparities in oncology clinical trial participation continue to pose significant challenges. Despite initiatives by the NCI and FDA to address these disparities through policies established in 2017, notable gaps in both cancer treatment and clinical trial involvement persist. There is a lack of comprehensive data regarding minority participation in clinical trials for FDA-approved urothelial cancer therapies in the post-COVID-19 context. Methods: From 2020 to 2024, we examined data from 2,755 patients recruited in eight industry-sponsored clinical trials (BCL2001, CheckMate 274, CheckMate 901, EV-302, KEYNOTE 057, CS-003, QUILT-3.032, TROPHY) that led to the FDA approval of new agents or indications for urothelial cancer. We assessed and tabulated the reporting of racial demographics within these trials, employing chi-square statistics and machine learning algorithms to compare participation among White, Black, Asia and Hispanic patients against SEER data on urothelial cancer incidence. Results: Race data was reported in 7 (BCL2001, CheckMate 274, CheckMate 901, EV-302, CS-003, QUILT-3.032, TROPHY) out of 8 trials (87.5%), but only 5 (CheckMate 274, CheckMate 901, EV-302, CS-003, TROPHY) of these trials (71%) included data on Black and Asian populations alongside White participants. Notably, none of the trials reported date on Hispanic participants. Our analysis revealed that in the 7 trials providing race data, 79% of participants were White, indicating overrepresentation (p=0.013). among the 5 trials with comprehensive race reporting, Blacks were unrepresented at 2.3% (p=0.001), while Asians constituted 10%, showing no statistical significance (p=0.90) in difference in representation. No data was available for Hispanics. Conclusions: The continued underrepresentation of minorities in FDA-approved clinical trials for urothelial cancer is a pressing concern still in the post-COVID-19-era. To rectify these issues, it is essential to implement policies that improve data collection and standardize ethnic nomenclature. Furthermore, international collaborative trials should prioritize separate data reporting for U.S. participants, utilizing NCI SEER nomenclature to endure accurate representation and analysis.

Associations between protein biomarkers and adverse pathologic features in MRI-mapped prostate cancers: An interim analysis.

Journal of Clinical Oncology Wesley Hauwei Chou, Solange Bassale, Tao Liu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.405

405 Background: While standard mpMRI has shown benefit in increasing detection of clinically significant prostate cancer, it is limited in its ability to detect small lesions, low Gleason scores, and certain tumor architectures. Proteomics may supplement imaging and enhance prediction of clinical outcomes. We investigated associations between MRI-mapped tumors and protein levels obtained from radical prostatectomy (RP) specimens and correlated them to adverse pathology features. Methods: This was an interim analysis of a planned cohort of 124 subjects. Patients underwent routine preoperative mpMRI and whole-mount histopathology after RP, with proteomic analysis performed on tissue from MRI-mapped tumors. A panel previously shown to improve prediction of distant metastasis in RP patients included five proteins: TGFβ-1, SPARC, FOLH1 (PSMA), CAMKK2, and tumor PSA. Protein concentrations were log transformed. Logistic regression assessed protein associations with adverse pathologic features, including extracapsular extension (ECE), seminal vesicle invasion (SVI), lymph node invasion (LNI), Gleason score ≥8, and a composite of these findings. Multivariate analyses were adjusted by patient age, PSA, Gleason Grade Group, and T stage at diagnosis. Results: 61 patients had proteomic data; mean age at diagnosis was 64 years and mean PSA at diagnosis 10 ng/dL. ECE was present in 67%, SVI 20%, LNI 21%, and Gleason score ≥8 26%; 72% had at least one adverse pathologic feature. On initial multivariate analysis of proteins alone, TGFβ-1 significantly correlated with LNI (odds ratio [OR] 24.4 [95% confidence interval (CI) 3.7-160.2], p = 0.0009) and composite adverse pathology (OR 3.1 [95% CI 1.0-9.3], p = 0.05). Even after including clinical characteristics in the model, TGFβ-1 still significantly correlated with LNI (Table). None of the other proteins significantly correlated to these markers of adverse pathology. Conclusions: In this study assessing protein associations with MRI-identified prostate tumors, TGFβ-1 was strongly predictive for LNI. TGFβ signaling has been associated with both prostate cancer suppression and promotion depending on context. Further investigation will assess if the combination of proteins in the panel is more predictive of adverse pathology. Multivariate logistic regression analyzing association between proteins and lymph node invasion. Protein Odds ratio (95% CI) p-value TGFβ-1 235.0 (4.5-N/A) 0.007* SPARC 1.4 (0.3-7.3) 0.7 FOLH1 0.8 (0.3-2.4) 0.7 CAMKK2 2.0 (0.7-5.8) 0.2 PSA 2.0 (0.7-5.6) 0.2 Protein concentrations were log transformed and models included patient age, PSA, Gleason Grade Group, and clinical T-stage at diagnosis.

Genome wide association study reveals novel associations with face morphology

PLoS ONE Aamer Alshehhi, Mira Mousa, Guan K. Tay et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0299660

Genome-wide association studies (GWAS) on the Middle Eastern population, including the United Arab Emirates (UAE), have been relatively limited. The present study aims to investigate genotype-face morphology associations in the UAE population through Genome Wide Association Studies (GWAS). Phenotypic data (44 face measurements) from 172 Emiratis was obtained through three-dimensional (3D) scanning technology and an automatic face landmarking technique. GWAS analysis revealed associations of 19 genetic loci with six face features, 14 of which are novel. The GWAS analysis revealed 11 significant relationships between 44 face parameters and 242 SNPs, exceeding the GWAS significance threshold. These phenotypes were previously associated with body height, craniofacial defects, and facial characters. The most significant associations of these genetic variations were related to six main facial features which were facial convexity, left orbital protrusion, mandibular contour, nasolabial angle D, inferior facial angle B, and inferior facial angle A. To the best of our knowledge, this is the first GWAS study to investigate the association of SNP variations with face morphology in the Middle Eastern population.

Biopsychosocial based machine learning models predict patient improvement after total knee arthroplasty

Scientific Reports Karen Ribbons, Jodie Cochrane, Sarah Johnson et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88560-w

Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic papillary renal cell carcinoma: A GUARDIANS project.

Journal of Clinical Oncology Thomas Hilser, Can Aydogdu, Stefanie Zschaebitz et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.496

496 Background: Papillary (pRCC) renal cell carcinoma is a rare cancer. We evaluated real-world treatment outcomes of 1st line treatment in these cohorts in Germany. Methods: Data were collected retrospectively from 13 GU cancer centres in Germany. Patients (pts) with advanced or metastatic pRCC were eligible. Adverse events (AEs) were reported according to CTCAE 5.0. ORR was accessed according to local standard. Progression Free Survival (PFS) were calculated from start of treatment to progression or death. Descriptive statistics and KM-plots were utilized, where appropriate. Results: 131 suitable pts (82% male) with median age of 63 years (range 22-86) were included. ECOG 0-1 was 70%, nephrectomy was performed in 78%. IMDC scores were: 0 in 18%, ≥ 1 in 53%, missing in 29%. The most common sites of metastasis were lymphatic (66%) and pulmonary (41%) metastases. 52% patients received first-line IO-combinations (IO-IO: 18%, TKI-IO: 34%) and 40% patients TKI-monotherapy, predominantly sunitinib. AEs (all grades) with IO‐based or TKI mono therapy, were reported in 86% and 74%, CTCAE grade ≥ 3 in 46% and 22%, dose modifications were required in 35% and 26.0%. ORR and survival outcomes with median follow-up of 19 months (IQR 9-35) are described in the table. Conclusions: TKI-based therapy are frequently applied in pRCC. Our data support the use of IO+ TKI as a first-line standard for patients with pRCC. Major limitations were the retrospective data capture and short follow-up of our study. Additional analyses to tailor treatment strategies in patients with metastatic pRCC is warranted. ORR and survival outcomes of study population. Parameter All therapiesN=131 IO-ION=23 IO-TKIN=45 TKI monoN=51 OtherN=12 ORR (CR+PR) 34% 35 % 40 % 31 % 8% SD 29% 17 % 33 % 29 % 17% PD 23% 35 % 13 % 29 % 17% unknown 14% 13% 13 % 10 % 58 % mOS, months,95%-CI 32 .1 (24.4-39.9) 15.6(7.5-23.7) Not reached 27.6(19.7-35.7) 32.1(21.15-42.7) mPFS, months,95%-CI 8.5(6.5-10.4) 4.9(0.5-9.4) 9.2(3.5-15.0) 9.0(6.9-11.1) 8.5(0.0-22.8)

Real-world use of bone-modifying agents (BMA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the US.

Journal of Clinical Oncology Umang Swami, Yeonjung Jo, Chadi Hage Chehade et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.95

95 Background: Most pts with prostate cancer with bone metastasis experience symptomatic skeletal events (SSEs) [PMID: 23884473], leading to increased morbidity and mortality. BMAs have been approved since 2007 and are recommended in mCRPC to prevent SSEs in pts with bone metastases or a high risk of osteoporotic fracture. Herein, we sought to assess the real-world trends of BMA administration in pts with mCRPC. Methods: We used the de-identified nationwide Flatiron Health electronic health record (EHR)-derived database to extract pt-level data. Inclusion criteria: pts with mCRPC with available date of diagnosis of mCRPC and information on receipt of BMA. Pts were categorized into 2 cohorts based on BMA receipt (e.g., bisphosphonates, denosumab, teriparatide, romosozumab) or not. Treatment trends of BMA by year of mCRPC diagnosis were summarized using frequency and percentages. Baseline characteristics at the time of mCRPC diagnosis (age, race-ethnicity, practice type, insurance) were compared between cohorts using the Wilcoxon rank-sum and Chi-squared tests. Results: Of 24,105 pts with metastatic prostate cancer in the dataset, 14,112 with mCRPC were eligible and included. 7,990 (56.6%) received BMA while 6,122 (43.4%) did not. In BMA receipt cohort: median age was 75 (IQR 67 – 81), majority were White (61%), treated in community practice (87%) and had commercial health plan (80%). In BMA non receipt cohort: median age was 75 (IQR 68 – 82), majority were White (61%), treated in a community practice (78%), and had commercial health plan (76%). The use of BMA decreased over time from 56% in 2013 to 46% in 2024 (Table). Statistically significant differences existed between cohorts in race-ethnicity, practice type, and insurance (p < 0.001) and will be presented at the meeting. Conclusions: Despite recommendations to use BMAs in pts with mCRPC and bone metastasis or high risk of osteoporotic fracture, our findings reveal a low utilization rate of BMAs in mCRPC setting with a notable decline over time. This highlights the need to incorporate the use of BMAs in clinical practice and improve access to these agents. Trends by year of mCRPC diagnosis in receipt of the first BMA and frequency and percentage of each agent. Year 2013N = 549 2014N = 1035 2015N = 1223 2016N = 1345 2017N = 1441 2018N = 1346 2019N = 1469 2020N = 1380 2021N = 1352 2022N = 1393 2023N = 1196 2024N = 383 Receipt of BMA, n (%) 316 (56) 674 (65) 792 (65) 837 (62) 886 (61) 766 (57) 816 (56) 766 (56) 692 (51) 713 (51) 556 (46) 176 (46) Denosumab, n (%) 190 (60.1) 450 (66.8) 557 (70.3) 599 (71.6) 606 (68.4) 533 (70) 526 (64.5) 488 (63.7) 410 (59.2) 414 (58.1) 290 (52.2) 94 (53) Zoledronic acid, n (%) 120 (38) 220 (32.6) 228 (28.7) 233 (27.8) 270 (30.5) 225 (29) 281 (34.4) 273 (35.6) 277 (40) 295 (41.4) 258 (46.4) 82 (47) Teriparatide, other bisphosphonates, n (%) 6 (1.9) 4 (0.6) 7 (1) 5 (0.6) 10 (1.1) 8 (1) 9 (1.1) 5 (0.7) 5 (0.7) 4 (0.5) 8 (1.4) 0

Phase 1/2 OMAHA-01A substudy of oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Arif Hussain, Chris Garratt, Nan Li et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps300

TPS300 Background: Current treatments for mCRPC are associated with hormone dependence and the development of resistance. Therapeutic agents with novel mechanisms of action are needed for this patient population. Opevesostat (MK-5684; ODM-208) is an oral, nonsteroidal inhibitor of cytochrome P450 11A1 (CYP11A1), a catalyst of the first and rate-limiting step of steroid biosynthesis. In the phase 1/2 CYPIDES study, opevesostat demonstrated antitumor activity in patients with heavily pretreated mCRPC (1). OMAHA-U01 is an adaptive, open-label, rolling-arm, multicenter, phase 1/2 umbrella study that will evaluate the safety and efficacy of opevesostat-based investigational therapies in prostate cancer. Substudy 01A (NCT06353386) will evaluate opevesostat alone or in combination with other therapies in patients with previously treated mCRPC. Methods: Eligible patients have mCRPC that progressed during ADT ≤6 months before screening, and on/after 1-2 NHAs for metastatic or nonmetastatic hormone-sensitive prostate cancer and nonmetastatic or mCRPC. Prior treatment with ≤1 taxane for mCRPC is allowed. A safety lead-in phase for all opevesostat-based experimental combinations (~10 patients in each arm) will establish the recommended phase 2 dose (RP2D), followed by an efficacy phase (opevesostat alone, ≤100 patients; opevesostat-based combinations, ~40 patients each). Patients will be randomly assigned 1:1:1:1 to opevesostat 5 mg PO BID, opevesostat 5 mg PO BID + olaparib (RP2D), opevesostat 5 mg PO BID + docetaxel (RP2D), and opevesostat 5 mg PO BID + cabazitaxel (RP2D). The primary endpoint for the safety lead-in phase is safety and tolerability. Primary endpoints for the efficacy phase are safety and prostate-specific antigen response rate per Prostate Cancer Working Group criteria. 1. Fizazi et al. NEJM Evid. 2024. Clinical trial information: NCT06353386 .

Clinical experience with EMACO chemotherapy in male choriocarcinoma: A single-center study.

Journal of Clinical Oncology Gwanhyun Park, Inkeun Park, Shinkyo Yoon et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.640

640 Background: Choriocarcinoma is an aggressive subtype of germ cell tumor that frequently metastasizes and progresses rapidly. In gestational trophoblastic tumors in females, the etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMACO) regimen is commonly used, but there are limited reports of its use in male choriocarcinoma. The purpose of this study was to retrospectively describe the clinical outcomes of the EMACO regimen in male patients with pathologically confirmed or clinically highly suspected choriocarcinoma at a single institution. Methods: We conducted a retrospective review of the medical records of male patients who received at least one cycle of EMACO chemotherapy between February 2013 and September 2023 at a tertiary hospital in Korea. We analyzed their baseline characteristics, tumor response, survival outcomes, and adverse events. Resection of residual tumors following EMACO chemotherapy was also considered part of the treatment process. The evaluation of tumor response was based on radiological examinations and changes in tumor markers. Results: In total, 15 patients were included in the study with a median age of 26 years. During diagnosis, 7 patients were found to have pure choriocarcinoma cell components on pathological examination, but all patients had elevated beta-hCG levels (median 177,000 mIU/mL, range 312–11,478,883 mIU/mL). At the time of EMACO administration, lung metastasis was the most frequent, observed in 12 patients, followed by brain metastasis in 7 patients. Seven patients received EMACO chemotherapy as 1 st or 2 nd -line treatment. The median number of chemotherapy cycles was 6. Tumor marker reduction or a decrease in tumor size was observed in 11 patients. Residual tumor resection was performed immediately after EMACO treatment in 7 patients, and no recurrence was observed in 6 patients during the follow-up period. Regarding Grade 3-4 toxicity, anemia was observed in 10 patients, thrombocytopenia in 6 patients, neutropenia in all patients, and elevated alanine aminotransferase levels in 6 patients. The median OS was not reached, with a median follow-up time of 24 months and a median PFS of 10.2 months. Conclusions: EMACO chemotherapy is an effective regimen for male germ cell tumors with pathologically confirmed choriocarcinoma components or markedly elevated hCG levels, and it may offer a curative treatment option when combined with resection of residual tumors.

Validity evidence for assessing social-emotional psychological strengths in Colombian adolescents using the SEHS-S

PLoS ONE Diana Riaño-Hernández, Iwin Leenen, Angelli Ramírez-Conde et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0314488

Background Covitality is a multidimensional hierarchical construct of core psychological strengths that synergistically promote resilience and well-being and that has been shown to be effective in preventing mental health problems in individuals of different age groups. The Covitality Model consists of 12 first-order latent factors, 4 second-order factors, and one general higher-order Covitality factor. Purpose In this study, we aim at obtaining validity evidence for the assessment of Covitality in Colombian adolescents by means of the Social Emotional Health Survey-Secondary (SEHS-S). Method A sample of 1461 adolescents responded the SEHS-S and four other instruments that measure well-being and distress. The internal structure of the SEHS-S was examined through confirmatory factor analyses as well as its relations with other variables. Results The hierarchical factor structure of the SEHS-S was supported (with goodness-of-fit statistics: χ2 = 1727.6, df = 578, p < .001; RMSEA = .037; SRMSR = .044; AGFI = .962; CFI = .940; and NNFI = .935) and configural and metric invariance across gender and age was confirmed; however, the assumption of scalar invariance across males and females and across age groups was violated for some items. Furthermore, we found moderate to high correlations (r = .56 –.68) of Covitality with related constructs. Conclusion As a conclusion, the SEHS-S can be considered a valid tool to assess psychological strengths, well-being, and resilience (i.e., Covitality) in Colombian adolescents, though further research is needed to explore the differences in item functioning across gender and age.

Drug coated balloon angioplasty for de novo coronary lesions in large vessels: a systematic review and meta-analysis

Scientific Reports Cecilia Gobbi, Francesco Giangiacomi, Ioannis Merinopoulos et al. Feb 10, 2025 DOI: 10.1038/s41598-025-85734-4

Role of liquid biopsy in the detection of homologous recombination repair gene mutations (HRRm) in metastatic prostate cancer (mPC).

Journal of Clinical Oncology Soumaya Labidi, Parvaneh Fallah, Aida Salehi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.51

51 Background: The treatment landscape of mPC is rapidly evolving to include more precision therapies for patients with actionable genomic alterations. Specifically, deleterious aberrations in HRR genes (HRRm) confer sensitivity to PARP inhibitors (PARPi) which have demonstrated survival benefit in this context. Therefore, accurate identification of potentially actionable HRRm is indicated. Somatic testing for HRRm in archival tissue is inadequate due to poor DNA quality or lack of tissue availability in 30-40% of cases. We evaluated whether circulating tumor DNA (ctDNA) testing using liquid biopsies is associated with an increased rate of HRRm detection. Methods: This was a multi-institutional retrospective cohort study of mPC patients (pts) treated at the Jewish General Hospital or the McGill University Health Center, Montreal Canada, between 2021-23. Molecular data and treatment information was abstracted from chart review. Fisher’s exact test and Wilcoxon test were used to assess differences between groups. Results: We identified 282 mPC pts, mostly castration resistant (n=181, 64.2%). Median age was 67 years (43-92). Somatic and germline testing for HRRm was performed in 78.3% (n=224) and 23.4% (n=66) pts, respectively. Somatic testing was performed on tissue (n=164, 73.2%) or ctDNA from liquid biopsies (n=17, 7.5%) or both (n=43, 19.3%). Pathogenic somatic HRRm were detected in 37 pts (13.2%): BRCA2 (n=13), ATM (n=8), CHEK2 (n=4), PALB2 (n=4), CDK12 (n=4) and BRCA1 (n=2). Amongst pts with germline testing 10/66 (15.1%) had pathogenic HRRm, mostly BRCA2 (n=9) and 4/10 had detectable HRRm in tissue. The somatic HRRm detection rate was 14.6% (24/164) on tissue and 11.7% (2/17) in ctDNA, respectively. Pts who had both tissue and liquid biopsy experienced a higher detection rate (25.5%, 11/43) vs. either modality alone (P=0.064). Inconclusive results were less frequent in pts who had both liquid and tissue testing vs. tissue alone (2.3% vs 7.3%). Amongst the 10 pts who had discordant results between liquid and tissue tests, HRRm were more frequently identified in ctDNA (n=7) vs. tissue (n=3). Pts who had HRRm detected only in ctDNA, had significantly older tissue samples (median 5.1 years) compared to those who had HRRm detected only in tissue (median 0.2 years, P=0.0156). Conclusions: Our data highlight a potential role of implementing liquid biopsy to improve the detection rate of HRRm. We are currently conducting a multi-center prospective study to determine if liquid biopsy increases the rate of detection of HRRm compared to routine tissue testing, and therefore allows to identify more patients who are eligible to receive precision therapies.